Product Description
a selective nicotinic alpha-7 receptor (_7nAChR) partial agonist
Mechanisms of Action: nAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Alzheimer Disease|Schizophrenia|Cognitive Dysfunction
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01196065 |
BP25180 | P1 |
Completed |
Healthy Volunteers |
None |
2019-03-19 |
Treatments |
|
2008-004012-13 |
2008-004012-13 | P2 |
Completed |
Alzheimer Disease |
2010-11-19 |
2025-07-05 |
Treatments |
|
NCT00884507 |
WN22018 | P2 |
Completed |
Alzheimer Disease |
2010-11-01 |
2019-03-18 |
||
NCT00725855 |
P50 | P2 |
Unknown status |
Schizophrenia |
2009-03-01 |
2019-03-18 |
Treatments |
|
NCT00604760 |
MEM 3454-101 | P2 |
Unknown status |
Cognitive Dysfunction|Schizophrenia |
2009-02-01 |
2019-03-18 |
Treatments |
|
NCT00454870 |
MEM 3454-003 | P2 |
Completed |
Alzheimer Disease |
2007-10-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|